ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq:HGSI) today announced that Greg Norden, former Senior Vice President and Chief Financial Officer of Wyeth, has been appointed to the HGS Board of Directors.
“Greg Norden brings more than 25 years of leadership experience to HGS in financial management and strategy,” said H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences. “Greg has an outstanding record of accomplishment at one of the world’s most successful pharmaceutical companies, and we look forward to benefiting from his experience and insight as we continue our transition into a fully commercial biopharmaceutical company.”
During a 21-year career at Wyeth, Mr. Norden advanced through a series of senior financial management positions, including Senior Vice President and CFO of American Home Food Products; Senior Vice President and CFO of Wyeth Laboratories – North America; Executive Vice President and CFO of Wyeth Pharmaceuticals; and, from 2007 to 2010, Senior Vice President and CFO of Wyeth. Wyeth was acquired by Pfizer in October 2009 in a transaction valued at $68 billion. Prior to joining Wyeth, Mr. Norden worked in audit management at Arthur Andersen & Co.
Mr. Norden graduated from the State University of New York – Plattsburgh and received his M.S. in Accounting from Long Island University – C. W. Post. He has been licensed as a certified public accountant by the state of New York since 1984.
About Human Genome Sciences
Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.
For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences’ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences’ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences’ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.